Egle Therapeutics Alternatives & Competitors
12 companies similar to Egle Therapeutics — Modulating T-regulatory cells to balance immunity
Companies similar to Egle Therapeutics
ImCheck Therapeutics
Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic
Marseille, France
Tridek-One
We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseas...
Paris, France
Biond Biologics Ltd
Biond - Innovative immunotherapies and a pioneering intracellular delivery for biologics f...
Israel
Trillium Therapeutics Inc.
Clinical stage immuno-oncology company developing innovative therapies for the treatment o...
Cambridge, United States
Rival Readout
Competing with Egle Therapeutics? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Georgiamune Inc.
Georgiamune is reprogramming immune signaling pathways to redirect the immune system to fi...
Gaithersburg, United Stat...
-Biotech,-LLC.-logo.jpg "Hangzhou ImmuQuad(艾沐蒽) Biotech, LLC."){kind=logo}
Hangzhou ImmuQuad(艾沐蒽) Biotech, LLC.
杭州艾沐蒽生物科技有限公司
Hangzhou, China
Oncofactor Corporation
A Seattle-based innovator in cancer treatments, disrupting tumor-immune system signaling p...
GammaDelta Therapeutics
GammaDelta Therapeutics focuses on using γδ T cells to improve survival rates of patients...
London, United Kingdom
3T Biosciences
3T is an immunotherapy company developing next-generation, transformative therapies for br...
South San Francisco, Unit...
Immunaeon
Connecting Today's Science to Tomorrow's Cures
Buffalo, United States
Immutep Limited
The global leader in developing LAG-3 therapeutics (ASX: IMM, NASDAQ: IMMP)
Australia
About Egle Therapeutics
Egle Therapeutics is a biotechnology startup based in France, founded in 2020. The company focuses on modulating T-regulatory cells (Tregs) to balance immunity, employing a unique concept that involves starving Tregs while specifically targeting the most immunosuppressive ones. Egle Therapeutics recently secured a note...
developing breakthrough therapies designed to modulate regulatory T cells for the treatment of cancer and autoimmune diseases
patients with cancer and autoimmune diseases
Immunomodulation, T-regulatory Cells, Immunotherapy, Oncology, Autoimmune Diseases, Immune Suppressor, Regulatory T-cells, Paris, Emerging, Cancer Treatment, Immune System, Therapeutic Development
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Egle Therapeutics: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Egle Therapeutics on 11 Jun 2025. The 12 companies listed here were last checked between 11 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
